Skip to main
ELAN

ELAN Stock Forecast & Price Target

ELAN Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 25%
Buy 63%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

Elanco Animal Health demonstrates a strong market position with Simparica Trio leading the market with over 50% share and Credelio Quattro projected to increase its market share to 16.8% by 2026. Additionally, key product lines such as the Advantage Family and Seresto exhibit impressive year-over-year growth, with increases of 33% and 28% respectively in the third quarter of 2025. These trends reflect robust demand for Elanco's offerings and indicate a positive trajectory for the company's financial performance.

Bears say

Elanco Animal Health faces significant challenges that contribute to a negative outlook, primarily due to potential refinancing risks that could adversely affect earnings growth in 2026. Although the company’s revenue has increased by approximately 50%, the EBITDA margin has deteriorated by a few hundred basis points, suggesting a decline in profitability. Furthermore, while the recent EBITDA outperformance of $28 million in the second quarter indicates some operational strength, the overall financial trajectory remains concerning given the backdrop of rising financing costs and margin compression.

ELAN has been analyzed by 8 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 63% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Elanco Animal Health Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Elanco Animal Health Inc (ELAN) Forecast

Analysts have given ELAN a Buy based on their latest research and market trends.

According to 8 analysts, ELAN has a Buy consensus rating as of Feb 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $25.12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $25.12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Elanco Animal Health Inc (ELAN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.